Identifying new cancer treatments using molecular testing in community settings
Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")
This study is testing if using special tests to find specific markers in tumors can help doctors choose better treatments for people with advanced cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 572 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Glendale Adventist Medical Center d/b/a Adventist Health Glendale Academic / other |
| Locations | 1 site (Glendale, California) |
| Trial ID | NCT05692466 on ClinicalTrials.gov |
What this trial studies
This study aims to identify cancer patients with specific molecular markers in their tumors that can be targeted by therapeutic agents. It utilizes a comprehensive molecular testing panel to select the most appropriate treatment for patients with stage III and IV solid tumors. The study is observational and involves a pragmatic two-arm approach to assess treatment options based on molecular profiling. Patients will be required to provide informed consent and will be under the care of participating oncology sites.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with stage III or IV solid tumors who have not yet received treatment.
Not a fit: Patients who are minors, prisoners, pregnant women, or those unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment options for patients with advanced solid tumors.
How similar studies have performed: Other studies utilizing molecular testing for targeted cancer therapies have shown promising results, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who have given informed consent in accordance with the methods and procedures of this study * Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care * Patients who have not received treatment related to his/her cancer * Patients who are willing to sign a release of medical records to the research team * Male and female patients ≥18 years of age * Patients under oncology care of a participating site * Sufficient clinical status for collection of biospecimen samples within usual care * Patients who have insurance coverage for CMT Exclusion Criteria: * Patients considered minors in the jurisdiction where the protocol is conducted. * Patients who are prisoners and pregnant women. * Patients who cannot provide consent and did not sign a power of attorney.
Where this trial is running
Glendale, California
- Adventist Health Glendale — Glendale, California, United States (Recruiting)
Study contacts
- Study coordinator: Mihran H Shirinian, MD
- Email: mshirin@aol.com
- Phone: 818-543-7574
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.